Program
pitavastatin
Also written as “Pitavastatin”, “Pitavastatin (NK-104)” and “NK-104-CR”.
Its studies are mostly in Hypercholesterolemia · Hyperlipidemias · Renal Insufficiency · Dyslipidemias · Diabetes Mellitus, Type 2, led by 5 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Kowa | 180 open or running | phase 4since Dec 18, 2009 | Nov 4, 2005 | none ahead |
| JW Pharmaceutical | 80 open or running | phase 4since Mar 18, 2008 | Mar 18, 2008 | none ahead |
| Merck | 10 open or running | phase 1since Oct 12, 2017 | Oct 12, 2017 | none ahead |
| Orient Pharma | 10 open or running | phase 3since Oct 16, 2012 | Oct 16, 2012 | none ahead |
| tai-tien-pharmaceuticals-co-ltd | 10 open or running | phase 3since Jun 29, 2011 | Jun 29, 2011 | none ahead |
Also a collaborator on its studies: orient-europharma-co-ltd, kowa-pharmaceuticals-america-inc and Eli Lilly.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 14 studies since Nov 4, 2005.
- Jan 25, 2010Phase 4 study in Healthy VolunteersKowa · NCT01057433 · 24 enrolled · United States
- Jul 19, 2010Phase 4 study in HypercholesterolemiaJW Pharmaceutical · NCT01166633 · 200 enrolled
- Dec 7, 2010Phase 4 study in Primary DyslipidemiaKowa · NCT01256476 · 328 enrolled · United States
- Feb 18, 2011Phase 4 study in DyslipidemiasKowa · NCT01301066 · 252 enrolled · United States
- Jun 29, 2011tai-tien-pharmaceuticals-co-ltd's first study: phase 3 study in HyperlipidemiasNew to tai-tien-pharmaceuticals-co-ltdtai-tien-pharmaceuticals-co-ltd · NCT01386853 · 200 enrolled · Taiwan
- Jul 26, 2011Phase 1 study in HyperlipidemiasJW Pharmaceutical · NCT01406431 · 48 enrolled · Korea, Republic of
- Aug 22, 20112 phase 4 studies in HealthyKowa · NCT01422382, NCT01422369
- May 2, 2012Phase 1 study in Metabolic SyndromeKowa · NCT01595828 · 14 enrolled · United Kingdom
- Oct 16, 2012Orient Pharma's first study: phase 3 study in HypercholesterolemiaNew to Orient PharmaOrient Pharma · NCT01710007 · 202 enrolled · Taiwan
- Feb 4, 2014Phase 4 study in HyperlipidemiasJW Pharmaceutical · NCT02056847 · 313 enrolled · Korea, Republic of
- Jan 28, 2016Phase 3 study in HyperlipidemiasKowa · NCT02670434 · United States
- Jun 10, 2016Phase 3 study in HyperlipidemiasKowa · NCT02799758 · United States
- Oct 12, 2017Merck's first study: phase 1 study in Renal InsufficiencyNew to MerckMerck · NCT03311841 · 32 enrolled · United States
- Oct 6, 2020Phase 3 study in Primary HypercholesterolemiaJW Pharmaceutical · NCT04584736 · 283 enrolled · Korea, Republic of
TargetBeta
“HMG-CoA reductase inhibitor; HMG-CoA reductase inhibitor; HMG-CoA reductase inhibitor”ChEMBL 37, by rule
Other programs on HMGCR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Atorvastatinrule | Viatris | phase 4 | 186 |
| rosuvastatinrule | AstraZeneca | phase 4 | 184 |
| Simvastatinrule | Organon | phase 4 | 100 |
Studies
All 29 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT04584736Primary Hypercholesterolemia · Korea, Republic of | 3 | Completed | JW Pharmaceutical | Jul 16, 2020 | 283 |
| NCT03311841Renal Insufficiency · United States | 1 | Completed | Merck | Aug 2, 2018 | 32 |
| NCT02799758Hyperlipidemias · United States | 3 | Withdrawn | Kowa | Jul 2017 | 0 |
| NCT02670434Hyperlipidemias · United States | 3 | Withdrawn | Kowa | Jul 2017 | 0 |
| NCT02056847Hyperlipidemias · Korea, Republic of | 4 | Completed | JW Pharmaceutical | May 2017 | 313 |
| NCT01710007Hypercholesterolemia · Taiwan | 3 | Completed | Orient Pharma | Sep 2012 | 202 |
| NCT01595828Metabolic Syndrome · United Kingdom | 1 | Completed | Kowa | Jun 2012 | 14 |
| NCT01422382Healthy · United States | 4 | Completed | Kowa | Jun 2011 | 28 |
| NCT01422369Healthy · United States | 4 | Completed | Kowa | Jun 2011 | 28 |
| NCT01406431Hyperlipidemias · Korea, Republic of | 1 | Completed | JW Pharmaceutical | Aug 2011 | 48 |
| NCT01386853Hyperlipidemias · Taiwan | 3 | UNKNOWN | tai-tien-pharmaceuticals-co-ltd | Mar 2012 | 200 |
| NCT01301066Dyslipidemias · United States | 4 | Completed | Kowa | Mar 2013 | 252 |
| NCT01256476Primary Dyslipidemia · United States | 4 | Completed | Kowa | Jun 2011 | 328 |
| NCT01166633Hypercholesterolemia | 4 | Completed | JW Pharmaceutical | Nov 2010 | 200 |
| NCT01057433Healthy Volunteers · United States | 4 | Completed | Kowa | Dec 2010 | 24 |
| NCT01043094Renal Insufficiency · United States | 4 | Completed | Kowa | Apr 2010 | 16 |
| NCT00889226Hypercholesterolemia With Type2DM | 4 | Completed | JW Pharmaceutical | May 2009 | 161 |
| NCT00786734Angina, Stable · Korea, Republic of | 4 | Withdrawn | JW Pharmaceutical | May 2009 | 0 |
| NCT00701285Heart Failure · Korea, Republic of | 4 | Completed | JW Pharmaceutical | May 2013 | 70 |
| NCT00640276Hypercholesterolemia · Korea, Republic of | 4 | Completed | JW Pharmaceutical | Feb 2011 | 187 |
| NCT00344370Diabetes Mellitus, Type 2 · Denmark, Germany, India and more | 3 | Completed | Kowa | Apr 2008 | 214 |
| NCT00344175Hypercholesterolemia · Denmark, Netherlands, Spain and more | 3 | Completed | Kowa | Aug 2007 | 178 |
| NCT00330876Hypercholesterolemia · Denmark, Germany, Israel and more | 3 | Completed | Kowa | Dec 2007 | 545 |
| NCT00325780Hypercholesterolemia · Denmark, Finland, Germany and more | 3 | Completed | Kowa | Nov 2007 | 1,355 |
| NCT00309751Diabetes Mellitus, Type 2 · Denmark, Germany, India and more | 3 | Completed | Kowa | Jun 2007 | 418 |
| NCT00309738Hypercholesterolemia · Denmark, Netherlands, Spain and more | 3 | Completed | Kowa | Oct 2006 | 355 |
| NCT00257686Hypercholesterolemia · Denmark, Germany, Israel and more | 3 | Completed | Kowa | May 2006 | 962 |
| NCT00309777Hypercholesterolemia · Finland, Italy, Norway and more | 3 | Completed | Kowa | Oct 2006 | 857 |
| NCT00249249Dyslipidemias · Denmark, Finland, Germany and more | 3 | Completed | Kowa | 830 |
How it is read
Names in the registry
- “Pitavastatin”, 18 entries
- “pitavastatin”, 8 entries
- “Pitavastatin (NK-104)”, 3 entries
- “NK-104-CR”, 2 entries
- “pitavastatin single dose combined with ceftobiprole”, 1 entry
Conditions, from the studies’ own filings
- Hypercholesterolemia, 13 studies
- Hyperlipidemias, 5 studies
- Renal Insufficiency, 2 studies
- Dyslipidemias, 2 studies
- Diabetes Mellitus, Type 2, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.